Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Outcomes of Myeloma Patients with t(11;14) Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy

Jonathan L Kaufman, MD, Nisha Joseph, MD, Vikas A. Gupta, MD PhD, Charise Gleason, ANP, Craig C Hofmeister, MD MPH, Leonard Heffner, MD, Madhav V Dhodapkar, MD, Sagar Lonial, MD, Lawrence H. Boise, PhD, Ajay K Nooka, MD MPH

Blood (2018) 132 (Supplement 1): 3282.

https://doi.org/10.1182/blood-2018-99-119051

Published: 2018

Journal Articles

Efficacy of Induction Thearapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients

Nisha Joseph, MD, Vikas A. Gupta, MD PhD, Craig C Hofmeister, MD MPH, Charise Gleason, ANP, Leonard Heffner, MD, Lawrence H. Boise, PhD, Jonathan L Kaufman, MD, Madhav V Dhodapkar, MD, Sagar Lonial, MD, Ajay K Nooka, MD MPH

Blood (2018) 132 (Supplement 1): 3294.

https://doi.org/10.1182/blood-2018-99-119895

Published: 2018

Journal Articles

Impact of Early Progression on Long Term Outcomes Among Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy

Ajay K Nooka, MDMPH, Jonathan L Kaufman, MD, Charise Gleason, ANP, Nisha Joseph, MD, Craig C Hofmeister, MD MPH, Lawrence H. Boise, PhD, Leonard Heffner, MD, Madhav V Dhodapkar, MD, Sagar Lonial, MD

Blood (2018) 132 (Supplement 1): 3302.

https://doi.org/10.1182/blood-2018-99-120314

Published: 2018

Journal Articles

Differences in Presentation and Survival Outcomes for African American Patients with Newly Diagnosed Multiple Myeloma

Blood (2018) 132 (Supplement 1): 5647.

https://doi.org/10.1182/blood-2018-99-119948

Published: 2018

Journal Articles

Lenalidomide, Bortezomib, and Dexamethasone (RVD) As Induction Therapy in Newly Diagnosed Multiple Myeloma (MM)

Nisha Joseph, MD, Dhwani Almaula, MBBS, Charise Gleason, ANP, Leonard Heffner, MD, Lawrence H. Boise, PhD, Jonathan L. Kaufman, MD, Sagar Lonial, MD, Ajay Nooka, MDMPH

Blood (2017) 130 (Supplement 1): 3139.

https://doi.org/10.1182/blood.V130.Suppl_1.3139.3139

Published: 2017

Journal Articles

Clinical Efficacy of Daratumumab, Pomalidomide and Dexamethasone in Relapsed, Refractory Myeloma Patients: Utility of Retreatment with Daratumumab Among Refractory Patients

Ajay K Nooka, MD MPH, Nisha Joseph, MD, Larry H Boise, PhD, Charise Gleason, MSN, ANP-BC, AOCNP, Jonathan L. Kaufman, MD, Sagar Lonial, MD FACP

Blood (2016) 128 (22): 492.

https://doi.org/10.1182/blood.V128.22.492.492

Published: 2016

Journal Articles

Patterns of Relapse Among Myeloma Patients Post-Autologous Stem Cell Transplant

Prashanth Kumar, Nisha Joseph, MD, Dhwani Almaula, MPH, Lawrence H Boise, PhD, Jonathan L. Kaufman, MD, Charise Gleason, MSN, ANP-BC, AOCNP, Sagar Lonial, MD FACP, Ajay K Nooka, MD MPH

Blood (2016) 128 (22): 4524.

https://doi.org/10.1182/blood.V128.22.4524.4524

Published: 2016

Journal Articles

Role of PET/CT As a Measure of Minimal Residual Disease (MRD) Negativity Among Patients with Myeloma Post Autologous Stem Cell Transplant (ASCT)

Ajay K. Nooka, MD MPH, Jonathan L. Kaufman, MD, A. Tuba Karagulle Kendi, MD, Yan Li, Chikaodili O Obidike, Charise Gleason, MSN, ANP-BC, AOCNP, Lawrence H Boise, PhD, Sagar Lonial, MD

Blood (2015) 126 (23): 4202.

https://doi.org/10.1182/blood.V126.23.4202.4202

Published: 2015

Journal Articles

Efficacy and Safety of Triplet Versus Doublet Salvage Therapies Among Patients with Multiple Myeloma (MM) Experiencing Early Relapse: Meta-Analysis of Phase III Randomized Controlled Trials (RCTs)

Ajay K. Nooka, MD MPH, Jonathan L. Kaufman, MD, Madhusmita Behera, PhD, Charise Gleason, MSN, ANP-BC, AOCNP, Hannah Collins, ANP-BC, OCN, Vikas A. Gupta, MD PhD, Lawrence H Boise, PhD, Sagar Lonial, MD

Blood (2015) 126 (23): 5344.

https://doi.org/10.1182/blood.V126.23.5344.5344

Published: 2015

Journal Articles

Phase I Study of the Combination of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multiple Myeloma Research Consortium (MMRC) Clinical Trial

Jonathan L. Kaufman, MD, Todd Zimmerman, MD, Cara A Rosenbaum, MD, Ajay K. Nooka, MD MPH, Leonard T Heffner, MD, R. Donald Harvey, PharmD, Charise Gleason, MSN, ANP-BC, AOCNP, Colleen Lewis, MSN, ANP-BC, AOCNP, Cathy Sharp, RN, MN, OCN, Kenisha W Barron, B.S, CCRC, Sagar Lonial, MD

Blood (2014) 124 (21): 32.

https://doi.org/10.1182/blood.V124.21.32.32

Published: 2014

Journal Articles

Vorinostat, Bortezomib, Cyclophosphomide, Thalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients

Charise Gleason, MSN, ANP-BC, AOCNP, Jonathan L. Kaufman, MD, Ajay K. Nooka, MD MPH, Kelly Valla, PharmD, BCOP, Leonard T Heffner, MD, Aditya Singh Bisht, Sanjay Manubolu, Melanie Watson, Lawrence H. Boise, PhD, Sagar Lonial, MD

Blood (2014) 124 (21): 5773.

https://doi.org/10.1182/blood.V124.21.5773.5773

Published: 2014

Journal Articles

Colesevelam Hydrochloride for the Treatment of Lenalidomide Induced Diarrhea

Melanie Watson, RN, OCN, Ajay K. Nooka, MD MPH, Charise Gleason, MSN, ANP-BC, AOCNP, Kelly Valla, PharmD, BCOP, Jonathan L. Kaufman, MD, Sagar Lonial, MD

Blood (2014) 124 (21): 5779.

https://doi.org/10.1182/blood.V124.21.5779.5779

Published: 2014

Journal Articles

Bortezomib in Combination with Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin (V-DCEP) for the Treatment of Multiple Myeloma

Kelly Valla, PharmD, BCOP, Jonathan L. Kaufman, MD, Charise Gleason, MSN, ANP-BC, AOCNP, Lawrence H. Boise, PhD, Leonard T Heffner, MD, Sanjay Manubolu, Aditya Singh Bisht, Melanie Watson, Ajay K. Nooka, MD MPH, Sagar Lonial, MD

Blood (2014) 124 (21): 2139.

https://doi.org/10.1182/blood.V124.21.2139.2139

Published: 2014

Journal Articles

Down to the bitter end

Sagar Lonial, Charise Gleason

Blood (2014) 123 (20): 3061–3062.

https://doi.org/10.1182/blood-2014-04-565317

Published: 2014

Journal Articles

Using Serum Free Light Chain (SFLC) Ratio and Serum Protein Electrophoresis (SPEP) As a Substitute For 24-Hour Urine Studies In Myeloma Patients

Nishi N Shah, MBBS, Ajay K. Nooka, MD, MPH, Donald Harvey, Jonathan L. Kaufman, MD, Amelia Langston, MD, Dana Nickleach, PhD, Charise Gleason, MSN, ANP-BC, AOCNP, Leonard T Heffner, MD, Lawrence H. Boise, PhD, Sagar Lonial, M.D.

Blood (2013) 122 (21): 5358.

https://doi.org/10.1182/blood.V122.21.5358.5358

Published: 2013

Journal Articles

Lenalidomide, Bortezomib, and Dexamethasone (RVD) in Combination with Vorinostat As Front-Line Therapy for Patients with Multiple Myeloma (MM): Results of a Phase 1 Study

Jonathan L. Kaufman, MD, Jatin J. Shah, M.D., Jacob P. Laubach, MD, Alaina R. Mitchell, BS, Cathy Sharp, R.N., Colleen Lewis, MSN, ANP-BC, AOCNP, R. Donald Harvey, PharmD, Charise Gleason, MSN, ANP-BC, AOCNP, Daniela Casbourne, FNP-BC, AOCNP, Ajay K. Nooka, MD, MPH, FACP, Leonard T Heffner, MD, Paul G. Richardson, MD, Robert Z. Orlowski, M.D., Ph.D., Sagar Lonial, MD

Blood (2012) 120 (21): 336.

https://doi.org/10.1182/blood.V120.21.336.336

Published: 2012

Journal Articles

Impact of Body Mass Index (BMI) On Overall Survival in Myeloma

Mukesh Kumar, MD, Ajay K. Nooka, MD, MPH, FACP, Amelia Langston, MD, Charise Gleason, MSN, ANP-BC, AOCNP, Melanie Watson, Hannah Collins, ANP-BC, OCN, Daniela Casbourne, FNP-BC, AOCNP, Lawrence H. Boise, PhD, Jonathan L. Kaufman, MD, Edmund K. Waller, MD, PhD, Sagar Lonial, MD

Blood (2012) 120 (21): 4289.

https://doi.org/10.1182/blood.V120.21.4289.4289

Published: 2012

Journal Articles

Post-Transplant Platelet Recovery Kinetics and Its Association with Overall Survival in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HSCT)

Jie Li, Jillian Alyse Deppa, Zahir Ali, Michael Graiser, PhD, Amelia Langston, MD, Charise Gleason, Jessica Thomas, Edmund K Waller, MD PhD

Blood (2011) 118 (21): 2049.

https://doi.org/10.1182/blood.V118.21.2049.2049

Published: 2011

Journal Articles

The Improved Efficacy of Bortezomib Containing Induction Regimens (BCIR) Versus Non-Bortezomib Containing Induction Regimens (NBCIR) in Transplant-Eligible Patients with Multiple Myeloma (MM): Meta-Analysis of Phase III Randomized Controlled Trials (RCTs),

Ajay K. Nooka, MD, MPH, FACP, Jonathan L. Kaufman, MD, Madhusmita Behera, Charise Gleason, Amelia Langston, MD, Conor Ermst Steuer, MD, Christopher R Flowers, MD, Lawrence H. Boise, PhD, Sagar Lonial, MD

Blood (2011) 118 (21): 3994.

https://doi.org/10.1182/blood.V118.21.3994.3994

Published: 2011

Journal Articles

Bortezomib, Thalidomide, and Dexamethasone as Induction Therapy for Patients with Symptomatic Multiple Myeloma.

Jonathan L. Kaufman, MD, Charise Gleason, MSN, APRN, Leonard Heffner, MD, Sagar Lonial, MD

Blood (2007) 110 (11): 3605.

https://doi.org/10.1182/blood.V110.11.3605.3605

Published: 2007

NARROW

Outcomes of Myeloma Patients with t(11;14) Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy

Efficacy of Induction Thearapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients

Impact of Early Progression on Long Term Outcomes Among Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy

Differences in Presentation and Survival Outcomes for African American Patients with Newly Diagnosed Multiple Myeloma

Lenalidomide, Bortezomib, and Dexamethasone (RVD) As Induction Therapy in Newly Diagnosed Multiple Myeloma (MM)

Clinical Efficacy of Daratumumab, Pomalidomide and Dexamethasone in Relapsed, Refractory Myeloma Patients: Utility of Retreatment with Daratumumab Among Refractory Patients

Patterns of Relapse Among Myeloma Patients Post-Autologous Stem Cell Transplant

Role of PET/CT As a Measure of Minimal Residual Disease (MRD) Negativity Among Patients with Myeloma Post Autologous Stem Cell Transplant (ASCT)

Efficacy and Safety of Triplet Versus Doublet Salvage Therapies Among Patients with Multiple Myeloma (MM) Experiencing Early Relapse: Meta-Analysis of Phase III Randomized Controlled Trials (RCTs)

Phase I Study of the Combination of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multiple Myeloma Research Consortium (MMRC) Clinical Trial

Vorinostat, Bortezomib, Cyclophosphomide, Thalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients

Colesevelam Hydrochloride for the Treatment of Lenalidomide Induced Diarrhea

Bortezomib in Combination with Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin (V-DCEP) for the Treatment of Multiple Myeloma

Down to the bitter end

Using Serum Free Light Chain (SFLC) Ratio and Serum Protein Electrophoresis (SPEP) As a Substitute For 24-Hour Urine Studies In Myeloma Patients

Lenalidomide, Bortezomib, and Dexamethasone (RVD) in Combination with Vorinostat As Front-Line Therapy for Patients with Multiple Myeloma (MM): Results of a Phase 1 Study

Impact of Body Mass Index (BMI) On Overall Survival in Myeloma

Post-Transplant Platelet Recovery Kinetics and Its Association with Overall Survival in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HSCT)

The Improved Efficacy of Bortezomib Containing Induction Regimens (BCIR) Versus Non-Bortezomib Containing Induction Regimens (NBCIR) in Transplant-Eligible Patients with Multiple Myeloma (MM): Meta-Analysis of Phase III Randomized Controlled Trials (RCTs),

Bortezomib, Thalidomide, and Dexamethasone as Induction Therapy for Patients with Symptomatic Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only